A novel enzymatic activity of WSTF and its role in tumorigenesis
A novel enzymatic activity of WSTF and its role in tumorigenesis
批准号:
8122501
负责人:
zhuo Andrew Xiao
金额:
$24.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2013-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
My long term research Interest is to investigate epigenetic mechanisms to suppress tumorigenesis. Recent
studies suggest that the DNA damage response (DDR) induced by aberrant proliferation, may be one of the
barriers at early stage of tumorigenesis to prevent genomic instability. One hallmark of DDR at early stage
of tumorigenesis Is histone H2A.X S139 phosphorylation (known as H2A.X). This phosphorylation event is
well-known for its demarcation of compact chromatin structures formed during DDR induced by DNA
damage agents. In keep with these observations, H2A.X deficiency accelerates the tumor progression on a
p53 deficient background in mice. Our preliminary studies have identified a new mark phosphorylation on
H2A.X, tyrosine 142 and its kinase, WSTF (William-Beuren Syndrome Transcription Factor), a gene
frequently deleted In human William-Beuren Syndrome (WS). Our studies have demonstrated that WSTF
has an intrinsic tyrosine kinase activity via its unconventional kinase domain, which shares no homology
with any known kinase fold. Interestingly, our recent data indicate that the WSTF and ATM may form a
"feed-forward" loop to regulate DDR induced by DNA damage treatment, including H2A.X (S139)
phosphorylation. WSTF may also play a critical role in DDR initiated by aberrant proliferation; therefore, it
may suppress tumorigenesis by preventing genomic instability. In the mentored phase, I will test if WSTF
function is regulated by the ATM/R kinases. A parallel objective in this phase is to develop H2A.X "designer
chromatin" in collaboration with Dr. Tom Muir's lab (Rockefeller University). In the independent phase, I will
test WSTF function for suppressing tumorigenesis in genetically modified mouse models. The goal of the
mentored phase (I year) is to develop key methodologies and reagents for the independent phase and
beyond. At the same time, I will apply for independent positions. The excellent environment in Drs. Allis
and Muir's lab will facilitate my research in the mentored phase and my transition to an independent
investigator. The proposed research at the independent phase (3 years) will pave the road to launch my
future investigations to Identify novel epigenetic mechanisms to suppress tumorigenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel epigenetic mechanism in early embryogenesis
-
批准号:10799233
-
项目类别:
-
资助金额:$19.39万
-
财政年份:2020
-
负责人:zhuo Andrew Xiao
-
依托单位:
A novel epigenetic mechanism in early embryogenesis
-
批准号:10369001
-
项目类别:
-
资助金额:$46.0万
-
财政年份:2020
-
负责人:zhuo Andrew Xiao
-
依托单位:
A novel epigenetic mechanism in early embryogenesis
-
批准号:10584485
-
项目类别:
-
资助金额:$46.0万
-
财政年份:2020
-
负责人:zhuo Andrew Xiao
-
依托单位:
Investigate Novel Epigenetic Silencing Mechanisms in Mouse ESCs
-
批准号:9034611
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2015
-
负责人:zhuo Andrew Xiao
-
依托单位:
Investigate Novel Epigenetic Silencing Mechanisms in Mouse ESCs
-
批准号:9221346
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2015
-
负责人:zhuo Andrew Xiao
-
依托单位:
Investigate Novel Epigenetic Silencing Mechanisms in Mouse ESCs
-
批准号:8860450
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2015
-
负责人:zhuo Andrew Xiao
-
依托单位:
A novel enzymatic activity of WSTF and its role in tumorigenesis
-
批准号:8132579
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2009
-
负责人:zhuo Andrew Xiao
-
依托单位:
A novel enzymatic activity of WSTF and its role in tumorigenesis
-
批准号:7662654
-
项目类别:
-
资助金额:$5.36万
-
财政年份:2009
-
负责人:zhuo Andrew Xiao
-
依托单位:
A novel enzymatic activity of WSTF and its role in tumorigenesis
-
批准号:8036443
-
项目类别:
-
资助金额:$7.2万
-
财政年份:2009
-
负责人:zhuo Andrew Xiao
-
依托单位:
A novel enzymatic activity of WSTF and its role in tumorigenesis
-
批准号:8279098
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2009
-
负责人:zhuo Andrew Xiao
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: